Dr Reddy’s launches stomach, esophagus problems treatment drug in the US


Drug main Dr Reddy’s Laboratories on Monday stated it has launched Lansoprazole delayed launch orally disintegrating tablets, used to deal with sure abdomen and esophagus problems, in the US market. The product is a therapeutic equal generic model of Prevacid SoluTab delayed launch orally disintegrating tablets authorised by the US Food and Drug Administration (USFDA).

In a regulatory submitting, Dr Reddy’s laboratories introduced launch of Lansoprazole DR (delayed launch) orally disintegrating tablets.

Quoting IQVIA Health knowledge, Dr Reddy’s stated the Prevacid model and generic had US gross sales of roughly USD 87 million for the most up-to-date 12 months ending in December 2020.

Dr Reddy’s Lansoprazole DR orally disintegrating tablets can be found in 15 mg and 30 mg tablets in unit-dose packages of 100.

Shares of Dr Reddy’s Laboratories have been buying and selling 1.50 per cent decrease at Rs 4,615 apiece on BSE.

This feed is routinely revealed by way of economictimes.indiatimes.com